Figure 5A shows that the expression constitutively-active 4E-BP1 reduces the level of the PLK1 protein, consistent with the RPPA results. Auranofin also reduced the level of the PLK1 protein in Ewing (Figure 5B) and other (Figure 5C) sarcoma cell lines. In previous work, we identified that inhibition of mTORC1/2 activates 4E-BP1 and inhibits protein synthesis in sarcoma cell lines (12). Figure 5D shows that treatment of sarcoma cell lines with the mTORC1/2 inhibitor TAK-228 activates 4E-BP1 and downregulates the level of the PLK1 protein (Figure 5D). The gene discussed is PLK1; the disease is sarcoma.